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inflammation, fibrosis, and the immune
response
Bridget P. Keenan1,2* , Lawrence Fong1,2 and Robin K. Kelley1,2
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis.
Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and
durable responses from immune checkpoint inhibition in subsets of HCC patients across disease etiologies. The
majority of HCC arises in the context of chronic inflammation and from within a fibrotic liver, with many cases
associated with hepatitis virus infections, toxins, and fatty liver disease. Many patients also have concomitant cirrhosis
which is associated with both local and systemic immune deficiency. Furthermore, the liver is an immunologic organ
in itself, which may enhance or suppress the immune response to cancer arising within it. Here, we explore the
immunobiology of the liver from its native state to chronic inflammation, fibrosis, cirrhosis and then to cancer, and
summarize how this unique microenvironment may affect the response to immunotherapy.
Keywords: Immunotherapy, Hepatocellular carcinoma, Checkpoint blockade, Liver cancer, Immunology, Fibrosis
Main text
Introduction
Hepatocellular carcinoma (HCC) is a disease with both a
grim prognosis and rising incidence. The most up to
date estimates demonstrate a median overall survival of
9 months for all stages of untreated HCC, a number that
worsens with increasing Barcelona Clinic Liver Cancer
(BCLC) stage [1]. In the world, liver cancer is the third
leading cause of cancer mortality while in the United
States, it is the fourth highest cause [2, 3]. The rising in-
cidence of liver cancer in the United States is attributed
to the epidemics of hepatitis C virus infection and non-
alcoholic fatty liver disease [4, 5]. For early stage HCC,
standard of care treatments include resection, localized
therapies such as ablation and radiation, and liver trans-
plantation [6]. Until recently, the only first line systemic
therapy approved for advanced HCC was the anti-
angiogenic multikinase inhibitor sorafenib, based upon
prolongation of median survival by approximately 3
months with low rates of tumor radiographic response,
attributed to a mechanism of disease stabilization [7].
Immunotherapy is a cancer treatment strategy that has
been explored for many years but only recently has seen
clinical success, mainly in the form of immune checkpoint
inhibitors. Antibodies to the immune checkpoints PD-1,
CTLA-4, and PD-L1, have proved to be relatively safe and
beneficial in treating triple negative breast cancer, renal
cell carcinoma, melanoma, urothelial carcinoma, squa-
mous cell carcinomas of the head and neck, Merkel-cell
carcinoma, and non-small cell lung cancer, among others
[8–14]. Checkpoint inhibition (CPI) blocks the negative
regulatory signals either directly on T cells or on cells that
interact with T cells (such as tumor cells, stromal cells,
and antigen-presenting cells), providing a stimulus to pre-
existing anti-tumor immunity. Recently, two PD-1 inhibi-
tory monoclonal antibodies, pembrolizumab and nivolu-
mab, received regulatory approvals in the second-line
setting for advanced HCC as monotherapy [15, 16]. There
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is also early phase clinical trial data demonstrating activity
from anti-CTLA-4 inhibition alone and in combination
with transcatheter arterial chemoembolization (TACE) or
ablation in a subset of patients [17, 18]. Response rates
range from 10 to 25% among the different checkpoint in-
hibitors used, and clinical data are reviewed more exten-
sively elsewhere [19, 20]. Moreover, despite the potential
concern for relatively worse toxicity related to CPI due to
already poor liver function in the HCC population, overall
clinical trials have shown an acceptable safety profile for
HCC patients, with rates of immune-related toxicity simi-
lar to that in patients with other tumor types and without
underlying hepatic dysfunction [21, 22].
The site of HCC development, the liver, makes immuno-
therapy a promising yet complicated strategy for treatment.
First, the liver itself is an immune organ, with rich popula-
tions of immune cells, some of which are unique to the liver
such as Kupffer cells [23]. As there are elements that can pro-
mote both tolerance and anti-tumor immunity within the
liver, evidence for the use of CPI in HCC must be inferred
from model systems and from the clinical data. In other solid
tumor types, metastases to the liver portend a poor response
to CPI and are associated with decreased tumor infiltration of
CD8+ T cells, demonstrating the power of the liver to gener-
ate tolerance to tumors derived from other sites [24]. Multiple
examples from mouse models further substantiate the induc-
tion of systemic tolerance when exogenous antigens are
expressed in hepatocytes, an effect mediated by T regulatory
cells (Tregs) [25, 26]. Conversely, NK and NK T cells are
thought to be potent anti-cancer effector cells, of which the
liver has a particular abundance [27–29]. Next, upwards of
80–90% of HCC arises in the context of underlying liver in-
jury which can progress to fibrosis or cirrhosis; therefore, it is
important to take into account the variable effects on the im-
mune microenvironment in this state of fibrosis and chronic
inflammation [30]. Lastly, the toxic and viral insults that pro-
mote carcinogenesis in the liver may drive immunosuppres-
sion directly through host/viral interactions or via chronic
inflammation, although conversely, pathogen-associated mol-
ecules could serve as a source of neo-antigens to be recog-
nized by effector T cells [31]. Thus, there is a tightly
interwoven, exceedingly complex, relationship of chronic in-
flammation and the anti-cancer immune response in the liver
which may represent an opportunity for CPI in HCC, but also
demands thoughtfully designed treatment strategies to sub-
vert suppressive mechanisms.
Normal liver biology: a complex balance between
tolerance and immunity
The liver is an immune organ made up in bulk by hep-
atic parenchymal cells. Besides the biliary epithelium,
the majority of the remaining 20 % are non-parenchymal
cells such as stellate cells, macrophages, NK, and T cells
including TCRγδ T cells (Table 1, Fig. 1) [32, 33]. The
unique anatomy of the liver puts lymphocytes in direct
apposition to hepatocytes through the lack of a base-
ment membrane in liver sinusoids [32]. Due to the
chronic antigen load from the gastrointestinal tract, the
liver needs to maintain a level of tolerance to balance
elimination of gut bacterial pathogens while avoiding se-
vere inflammation induced by non-pathogenic gut com-
mensals. The liver also serves as a major producer of
immune-related molecules like C-reactive protein (CRP)
and soluble pattern recognition receptors (PRRs) for
molecules derived from pathogenic organisms, thus play-
ing a central role in systemic inflammation and immun-
ity [33].
There are many cell types and molecules involved in
maintaining tolerance to gut antigens. Kupffer cells, which
are tissue macrophages that develop independent of bone
marrow-derived infiltrating monocytes, are located in the
lumen of liver sinusoids and are exposed to microbial
products, comprising the first line of defense (and toler-
ance) to pathogens [34]. Kupffer cells are activated by
LPS, the complement system, and other pathogen-
associated molecular patterns (PAMPs), through the ex-
pression of Toll-Like Receptors (TLRs), including TLR2,
TLR3, and TLR4, to recognize microbial antigens and sig-
nals from damaged hepatocytes [23, 35]. The cytokines
produced by Kupffer cells in response to TLR signaling
subsequently recruit and activate neutrophils [35, 36].
Neutrophils ingest bacteria, undergo apoptosis following
destruction of pathogens, and then are cleared by Kupffer
cells which dampens inflammation [36]. Compared to
monocyte-derived macrophages, Kupffer cells favor toler-
ance by expression of IL-10 which induces Tregs and PD-
L1 under steady-state conditions [23, 37]. Kupffer cells are
also the first line of defense from cancer cells derived from
other organs that metastasize to the liver [38]. Further
contributing to tolerance, monocytes and dendritic cells
(DCs) can be recruited to the liver from the bone marrow;
once there, cytokines such as macrophage colony-
stimulating factor and hepatocyte growth factor induce a
tolerogenic phenotype [39].
Two non-bone marrow-derived cell types unique to
the liver, liver sinusoidal endothelial cells (LSECs) and
hepatic stellate cells (HSCs), are critical to these in-
teractions with gut flora and mediation of tolerance
by the liver. Liver sinusoidal endothelial cells (LSECs)
are specialized endothelial cells which sample portal
venous blood and act as antigen-presenting cells
(APCs) with the ability to cross-prime T cells [40,
41]. LSECs constitutively express TLR4 resulting in
NFκB signaling and produce inflammatory cytokines
and reactive oxygen species in response to LPS [35,
42]. HSCs are specialized fibroblasts that can transi-
tion to myofibroblasts capable of producing extra-
cellular matrix proteins which can lead to fibrosis and
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Table 1 Immune cell functions and alterations across the spectrum of healthy liver, fibrosis, and hepatocellular carcinoma
Condition
Cell type Healthy Liver References Fibrosis and chronic
inflammation
References Hepatocellular carcinoma References
CD8+ T cell Provide protection against
infection
[32] Progressive dysfunction and
exhaustion, PD-1 upregulation
with chronic inflammation and
viral infection
[90] Anti-tumor antigen-specific re-
sponses detected; Progressive
dysfunction and exclusion
from tumors, upregulated ex-
haustion markers, low produc-
tion of granzyme B and
perforin, decreased
proliferation
[96, 98,
116, 124–
126]
CD4+ Treg Antigen-specific tolerance;
Readily expand following
interaction with HSCs, Kupffer
cells, and LSECs
[25, 26,
37]
Secrete IL-10 and TGFβ; Inhibit
CD8+ T cell responses; Pro-
mote B cell activation and pro-
duction of IgG through CD40-
CD40L interaction
[84, 85] Increased numbers of Tregs
found within liver tumors;
Suppress CD8+ T cell
production of perforin and
proliferation; Inhibit CD4+
effector T cell proliferation;
Suppress NK function
including cytotoxicity and IFNγ
production
[96–98,
107]
CD4+ Th cell Anti-microbial protective
immunity; Regulators of pro-
and anti-inflammatory signals
[32, 37] Decreased numbers of naïve
CD4+ T cells in circulation in
cirrhotic patients; Increased
numbers of Th17 cells, IL-17
can promote fibrosis via acti-
vation of stellate cells
[37, 83, 87,
88]
Elevated CD4/CD8 ratio
predictive of recurrence free
survival; Increased expression
of PD-1 and CTLA-4, De-
creased cytokine secretion in
intra-tumoral CD4+ cells com-
pared to peripheral blood
CD4+ T cells
[96, 99]
B cell Not well characterized, few B
cells found in healthy liver
[32] Role not as well-defined;
found to be activated in
chronic liver disease
[85] Rarely found via IHC staining
of liver tumors, IgA-producing
cells suppress CD8+ T cells
[94, 113]
TCRγδ T cell Recognition of peptide and
non-peptide ligands; Innate-
like and adaptive T cell protec-
tion from pathogens
[33] Production of pro-
inflammatory IL-17; Recruit-
ment of CD8+ T cells and Th1
cells; Killing of HSCs; Promote
monocyte differentiation into
MDSCs
[37, 86] Possible anti-tumor
cytotoxicity
[118]
Kupffer cell Induction of tolerance to
commensal bacteria and food
particles; Recruit Tregs;
Recruitment and clearance of
neutrophils; Stimulate T cell
response to infection; Recruit
and activate NK cells via IL-12
and cell:cell contact
[23, 28,
34–37, 39,
63]
Lose tolerogenic properties
under inflammatory
conditions; Secrete reactive
oxygen species, TGFβ, PDGF,
TNFα, and matrix
metalloproteinases; Activate
HSCs
[23, 33, 61,
65]
Protective against tumors via
clearance of tumor cells;
Suppression of T cell function
via PD-L1 expression
[38, 111]
MAIT cell Protection against bacteria;
React to lipid antigens
[37, 43,
44]
Exhausted phenotype with
upregulation of PD-1 and
CTLA-4; Capable of activating
HSCs
[92, 93] Potential anti-tumor cytotox-
icity; Excluded from tumors
and found at higher frequen-
cies in surrounding tissue
[44, 96]
NK cell Anti-viral protection through
cytokine production and
cytotoxicity
[28] Protect against fibrosis by
killing of HSCs and production
of IFNγ; Can induce liver injury
by worsening inflammation
[27, 28,
33]
Cytotoxic to tumor cells;
Impaired function (decreased
granzyme and perforin,
decreased cytotoxicity) and
decreased in number in
tumors and peripheral blood;
Decreased expression of
KIR2DL1 and KIR2DL3
[28, 94, 97,
100]
NK T cell Th1-like phenotype in the
presence of IL-12; Th2-like
phenotype in the presence of
IL-7. Type I NK T cells: Activate
neutrophils and HSCs, cause
hepatocyte death. Type II NK T
cells: Suppress pro-
[28, 45,
46]
Type I NK T cells: Activation of
HSCs and neutrophils,
production of IFNγ and IL-4
can worsen inflammation
[45, 72] Type I NK T cells associated
with tumor control; Impaired
cytotoxicity, decreased
expression of KIR2DL1 and
KIR2DL3
[71, 100]
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cirrhosis in some settings, as discussed further below;
they can also express MHC I and II and may play a
role in T cell priming [39, 42].
Unique innate and innate-like lymphocyte populations
exist in the liver, in higher abundance than in other or-
gans or peripheral blood. Natural killer (NK) cells make
up 25–40% of hepatic lymphocytes, with important roles
in protecting against fibrosis and defending against can-
cer and viruses through potent cytotoxicity as well as
production of IFNγ [28]. Mucosal-associated invariant T
cells (MAIT cells) have semi-invariant T cell receptors
(TCR) and are capable of mounting an immune response
to bacteria [43, 44]. Finally, NK T cells have semi-
invariant TCR chains and recognize endogenous and ex-
ogenous lipids including those derived from gut mi-
crobes. There are two types of NK T cells (I and II) with
type II being more numerous in humans; cross-
regulation between these cell types is essential for bal-
ance of pro and anti-inflammatory pathways in normal
liver [45, 46] (Table 1). Although more abundant in the
liver than in peripheral blood, NK T cells constitute a
relatively small fraction of the total liver T cells and
MAIT cells account for a larger portion of the innate-
like T cells in humans compared to mice [33, 37].
Conventional T cells must migrate through liver endo-
thelium and, through interaction with APCs mediated
by the integrins ICAM-1 and VCAM-1, can be triggered
to proliferate upon antigen encounter [37]. The liver
contains abundant adaptive and innate-like T cells that
protect against pathogens under normal conditions, with
higher numbers of CD8+ than CD4+ T cells, and higher
proportions of TCRγδ cells than in the peripheral blood
[32, 33, 47]. While Tregs are found at low levels (for ex-
ample, in comparison to the spleen) at steady state, they
are readily induced under tolerogenic conditions by
HSCs, LSECs, and Kupffer cells [37, 39]. Effector T cells
can be tolerized and clonally deleted following recogni-
tion of antigen by direct hepatocyte-induction of apop-
tosis or apoptosis due to incomplete activation [37].
Beyond cell types and liver anatomy, there are several
important tolerance-mediating molecules that have an
important role in healthy liver biology. Among them,
TGFβ has pleiotropic effects in the liver including pro-
moting fibrosis, carcinogenesis, and hepatocyte death,
and during the steady state, is involved in liver regener-
ation [48]. PD-L1 is constitutively expressed by sinus-
oidal cells and Kupffer cells, promoting tolerance both
under steady state and during viral infection [37, 49].
Additional examples of liver tolerance are documented
from the literature on liver transplantation. Given the
tolerogenic potential of the liver due to its role in medi-
ating host response to gut flora, perhaps it is not surpris-
ing that some liver transplant recipients can fully accept
their allograft and safely discontinue immunosuppressive
medications [50]. While the full mechanisms for this are
not yet fully elucidated, an NK and TCRγδ T cell gene
Table 1 Immune cell functions and alterations across the spectrum of healthy liver, fibrosis, and hepatocellular carcinoma
(Continued)
Condition
Cell type Healthy Liver References Fibrosis and chronic
inflammation
References Hepatocellular carcinoma References
inflammatory signaling
pathways.
Hepatic
stellate cell
Express MHC I and II; Induce
tolerance and anti-microbial
immunity; PD-L1 expression
leading to T cell apoptosis
[23, 39] Differentiate to myofibroblasts;
Secrete matrix
metalloproteinases,
extracellular matrix
remodeling; Secrete IL-6, TNFα
and TGFβ, Induce Th17 cells
and Tregs
[39, 59, 61,
65, 88]
Induce MDSC and polarize
monocytes to an
immunosuppressive
phenotype; Promote tumor
growth
[42, 64]
Liver
sinusoidal
endothelial
cell
Expression of MHC I and II;
Activate CD4+ and CD8+ T cell
responses; Induce tolerance
via PD-L1 expression; Induc-
tion of Tregs
[35, 39, 40,
50]
Impaired antigen-processing
and lower MHC II expression
in the setting of fibrosis re-
lated to high levels of circulat-
ing endotoxin
[41] Induce tolerance to tumor-
derived antigens; decrease
ability of dendritic cells to
stimulate T cell responses
[42, 47]
Bone
marrow-
derived
monocyte,
macrophage,
and dendritic
cell
Promote tolerance to
commensals and food
particles; Stimulate T cell
response to infection; More
tolerogenic than activating in
healthy liver
[39, 47] Dysfunctional antigen
presentation; Increased non-
classical monocytes; Produc-
tion of pro-inflammatory cyto-
kines (TNFα, IL-6, IL-1)
[41, 77, 78,
82, 83]
Conversion to MDSC capable
of suppressing effector T cells,
inducing Tregs, and
promoting tumor growth
through pro-angiogenic cyto-
kine production; Conversely,
can control tumors via induc-
tion of antigen-specific T cell
responses; Impaired ability to
penetrate tumor tissue
[23, 42, 47,
64, 104]
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signature identifies patients who establish tolerance of
their liver allograft [51]. Tregs are also important in me-
diating transplant tolerance in mouse models, and Treg
cell therapy is an active area of research in the transplant
community as a bridge to decreasing or discontinuing
immunosuppression post-transplant [52, 53].
Changes in the liver immune microenvironment with
progression from chronic inflammation to fibrosis
Both the systemic and local immune systems, as well as
components of innate and adaptive immune systems, are
altered in the setting of liver fibrosis and cirrhosis which
occurs due to chronic inflammation from toxins, infec-
tious agents, or other insults such as steatosis (Table 1,
Fig. 1). It is well-known clinically that cirrhotic patients
are systemically immunocompromised and infections
constitute a major source of mortality in end-stage liver
disease [54]. Bacterial infection and sepsis occur in part
due to increased bacterial translocation through a
“leaky” gastrointestinal barrier created by portal hyper-
tension, as well as due to weakened systemic and local
immunity [54–57]. The exact mechanisms related to the
initiation of inflammation from each type of insult are
reviewed extensively elsewhere and therefore are not dis-
cussed here. Rather, we focus on the general mecha-
nisms involved in fibrosis initiation and changes in the
immune status during progression to cirrhosis, an irre-
versible state that is the end-stage of fibrosis [58].
The main cell types involved in liver fibrosis initiation
appear to be HSCs and Kupffer cells. As a result of in-
flammation due to toxins such as alcohol, steatosis, or
viral infection, inflammatory cytokines activate HSCs
through TLR4, which then produce extracellular matrix
proteins such as collagen [59–61]. The cytokine IL-17
can drive production of pro-fibrogenic IL-6, TNFα and
TGFβ by HSCs and Kupffer cells [62]. Mouse models of
liver fibrosis demonstrate that under inflammatory con-
ditions, Kupffer cells no longer induce tolerance to ex-
perimental antigens as they do in normal liver [63].
During liver damage, Kupffer cells produce reactive oxy-
gen species, TGFβ, and platelet-derived growth factor
(PDGF) which activates HSCs [23, 33, 64]. Both Kupffer
Fig. 1 Liver immunobiology across a spectrum from healthy liver to inflammation and oncogenesis. Top panel: Viral and toxic insults drive inflammation in the
liver and alter the normal baseline response to gut commensals. Chronic inflammation can lead to alteration of normal immunity to both commensal organisms
and pathogens, and eventually, to oncogenesis. Bottom panel: General mechanisms underlying tolerance and immunity and interactions between various cell
types are outlined in each of the following states: healthy liver (left), fibrosis and cirrhosis (middle), and hepatocellular carcinoma (right). Cells that generally
maintain tolerance in healthy liver and promote immune suppression and oncogenesis are colored in red while cells that favor protective anti-microbial or anti-
tumor immunity are colored in blue
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cells and HSCs secrete matrix metalloproteinases during
chronic tissue injury which is mediated by TNFα and
TGFβ, promoting remodeling of the extracellular matrix
[65, 66]. Fibrosis and the buildup of extracellular matrix
leads to a hypoxic environment which results in VEGF
upregulation, which may later support tumor angiogen-
esis [64].
NK cells can protect against fibrosis via killing of acti-
vated HSCs, although can also drive inflammation [27,
28]. There is an inverse correlation between IFNγ-
producing NKp46high NK cells and the degree of fibrosis
in HCV-infected patients [67]. NK cell killing of HSCs
and production of IFNγ become suppressed over time
with advancing fibrosis and can be further suppressed by
alcohol consumption, as seen in a carbon tetrachloride-
induced fibrosis mouse model [68]. STAT1 signaling is an
important negative regulator of the fibrosis pathway, op-
posing the effects of TGFβ secreted by HSCs and support-
ing NK cell cytotoxicity [69]. HSCs become more resistant
to NK cell killing in later stages of fibrosis due to SOCS1
upregulation by HSCs [70]. As far as NK T cell popula-
tions’ role, there may also be duality based on the particu-
lar type of NK T cells involved. Type I NK T cells are
thought to be protective in acute liver injury but harmful
in chronic inflammation as they activate HSCs and neu-
trophils whereas in the setting of liver tumors, type I NK
T cells are associated with tumor control [45, 71, 72].
As liver injury and fibrosis progress, the extracellular
matrix becomes stiffer and the normal anatomy of liver
is altered which can then cause impaired production of
key immune molecules normally supplied by the liver
such as complement pathway proteins. Cirrhotic patients
have lower levels of C3 and C4 proteins than healthy
controls, associated with infections and mortality, while
in contrast and perhaps surprisingly, cirrhotic patients
had higher levels of mannan-binding protein and
opsonization [73, 74]. Another group that found while
mannose-binding lectin (MBL) is not necessarily lower
in cirrhotic patients compared to healthy controls, lower
levels of MBL in cirrhosis are associated with an in-
creased risk of infections [75]. As fibrosis progresses, a
dysfunctional immune response feeds forward the cycle
of inflammation. For example, patients with cirrhosis
have higher levels of TLR2 expression and circulating
endotoxin leading to exaggerated responses to bacterial
products [35]. However, the TLR signaling apparatus
can become dysfunctional rather than protective against
infection, as with more infections seen in cirrhotic pa-
tients with TLR4 polymorphisms and with TLR2 and
TLR4 dysfunction [55, 76]. Higher circulating levels of
endotoxin and IL-10 in cirrhotic patients compared to
healthy controls has been associated with “immune par-
alysis” – an inability of APCs to upregulate MHC and
present antigens effectively to T cells [41, 77]. Patients
with primary biliary cirrhosis were found to have defect-
ive Fc-Receptor mediated clearance of pathogen/anti-
body complexes, one proposed mechanism of the
impaired phagocytosis by APCs that is seen in liver dis-
ease, although this has not been seen in alcoholic cir-
rhotic patients [78]. Low albumin levels in cirrhotic
patients can drive neutrophil dysfunction; as albumin
binds excess endotoxin, elevated endotoxin levels lead to
chronic signaling in innate immune cells as a conse-
quence of hypoalbuminemia [79]. Other pro-
inflammatory molecules such as soluble CD163 and
MCP-1, activators of macrophages, also are increased in
the serum of cirrhotic patients [80, 81].
The chronic high levels of pro-inflammatory chemo-
kines and cytokines alters both systemic and local im-
mune cell subsets from that seen in patients without
liver disease. Compared to healthy controls, cirrhotic pa-
tients have an increased number of activated monocytes
and specifically, more non-classical (CD16+) monocytes,
which increase with progressive fibrosis and are capable
of activating HSCs [82, 83]. Cirrhotic patients with asci-
tes are found to have lower numbers of naïve CD4+ and
CD8+ T cells and higher numbers of activated CD4+ T
cells in the peripheral blood, as well as increased pro-
duction of IL-10 and TGFβ by T cells [83, 84]. Suppres-
sive Tregs expressing CD40 ligand occur in both mouse
models of liver injury and explanted hepatitis C (HCV)-
positive livers [85]. IL-17, capable of activating HSCs
and Kupffer cells to produce collagen via activation of
the STAT3 pathway, is mainly secreted by T cells, in-
cluding TCRγδ T cells [62, 86]. Tregs and Th17 cells are
both found to be increased in more advanced HBV-
related fibrosis compared to earlier stage fibrotic livers;
however, an elevated Th17/Treg ratio has been shown
to correspond with higher liver stiffness measurement, a
correlate of worsening liver fibrosis [87, 88]. Further-
more, chronic antigen stimulation can lead to T cell ex-
haustion, with upregulation of inhibitory receptors such
as PD-1 and progressive loss of polyfunctional cytokine
production [89]. Patients with chronic viral hepatitis
have exhausted viral-specific T cells; blockade of the
PD-1/PD-L1 pathway can partially reverse T cell dys-
function and has demonstrated some success in control
of chronic viral infection [90, 91]. In autoimmune liver
disease, MAIT cells are also found to be exhausted with
less IFNγ production and upregulation of PD-1 and
CTLA-4 is seen in autoimmune liver disease and hepa-
titis B infection [92, 93].
HCC tumor immunobiology in the fibrotic liver
microenvironment
Immune cell dysfunction is associated with HCC
HCC often arises in a background of inflamed liver due
to toxins and infectious agents, although there are
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patients in which de novo HCC occurs without known
fibrosis and cirrhosis, implying additional pathways to
oncogenesis such as viral insertional mutagenesis in the
case of hepatitis B virus. However, as the majority of pa-
tients that would be potential candidates for immuno-
therapy have HCC that occurs in the setting of liver
fibrosis/cirrhosis, we focus on the immune microenvir-
onment in the context of underlying fibrosis (Fig. 1).
Studies of the structural organization of liver tumor ver-
sus surrounding non-tumor liver tissue using immuno-
histochemistry (IHC), and more recently, single cell
RNA sequencing, show an immune gradient in the evo-
lution from fibrosis to cirrhosis to cancer. CD8+ T cells
can penetrate within the HCC microenvironment with
surrounding CD4+ T cells and B cells, particularly in a
subset of lymphocyte-rich tumors; however, in other
IHC studies, Tregs are most abundant in central areas
with CD8+ T cells restricted to borders of tumors [94–
96]. Tregs were enriched in the tumors of patients com-
pared to peripheral blood or surrounding tissue adjacent
to liver tumor [96]. CD20+ B cells and CD56+ NK cells
were rare via IHC staining of HCC tumors and sur-
rounding liver tissue; in particular, the CD56lowCD16+
NK cell subset, typically characterized by enhanced cyto-
toxicity, are decreased in peripheral blood of HCC pa-
tients versus healthy controls and within tumor versus
non-tumor liver, a finding associated with more Tregs
[94, 97]. Single cell analysis of immune cells from blood,
tumor, and surrounding “normal” liver in HCC patients
revealed predominant MAIT cells in non-tumor liver tis-
sue and a high frequency of CTLA-4high Tregs and
CD8+ T cells with upregulated exhaustion markers in
tumor tissue [96]. For the most part, Tregs had unique
TCRs suggesting they were not derived from other
CD4+ T cells, unlike CD8+ T cells which had higher de-
gree of overlap in their TCR repertoire between acti-
vated and exhausted cells [96].
While CD8+ T cells and NK T cells have been shown
to be protective against liver tumor cells in mouse
models, CD8+ TIL found within HCC in patients have
been shown to be dysfunctional with low production of
granzyme and perforin, low proliferation as measured by
Ki-67, and upregulation of exhaustion markers such as
TIM3, LAG3, PD-L1, and CTLA-4 [29, 98, 99]. Similarly,
NK and NK T cells in tumors of HCC patients were
found to have lower expression of KIR2DL1 and
KIR2DL3, receptors that modulate NK cytotoxicity,
compared to the NK and NK T cells in livers of healthy
controls [100]. The dysfunction of effector cells within
the tumor microenvironment is driven directly by HCC
tumor cells as well as indirectly by suppressive immune
cells recruited to tumors. Tumor-associated fibroblasts
can suppress NK cell cytotoxicity and cytokine produc-
tion via signaling intermediates such as prostaglandins
and indoleamine 2,3-dioxygenase (IDO) [101]. Soluble
MHC class I-related chain A (MICA), an inhibitory
NKG2D ligand, secreted by tumor cells, binds to NK
cells, thus impairing their ability to activate DCs [102].
Myeloid-derived suppressor cells (MDSC) and tumor-
associated macrophages, capable of inducing Tregs and
suppressing T cells, are present in HCC mouse models
[103] and patients [104]. Angiogenic factors such as
VEGF and FGF, are highly expressed by HCC cells and
recruit MDSC to tumors [105].
An immunosuppressive signaling axis drives progression
from chronic inflammation to HCC
Through analysis of paired tumor and non-tumor liver
samples from HCC patients, an immunosuppressive gra-
dient has been described with increased expression of
chemokine networks such as CXCR3/CXCL10 and
CCR6/CCL20 which enhances macrophage and Treg re-
cruitment to the liver [106, 107]. Layilin, a molecule not
previously known to be important in HCC and identified
with single cell RNA sequencing approaches, is upregu-
lated in CD8+ T cells and Tregs and can suppress IFNγ
production when over-expressed in CD8+ T cells [96].
TGFβ, a driver of liver fibrosis and oncogenesis via in-
duction of hepatocyte apoptosis and subsequent prolifer-
ation, can also promote oncogenesis as a key molecule
in the induction of Tregs, polarization of macrophages,
and suppression of effector T cells [108–110]. PD-L1,
expressed by Kupffer cells at baseline in healthy liver, is
more highly expressed in areas of tumor compared to
normal liver [111, 112].
Immune system dysfunction is driven by viral and non-viral
insults
While there is likely overlap in the final pathways lead-
ing to immune suppression and oncogenesis between
the different toxic and infectious insults that lead to
HCC, there are also distinct pathways associated with
various HCC etiologies. For example, IgA-producing
cells in patients with fatty liver disease-related HCC have
been implicated in driving oncogenesis via suppression
of CD8+ T cells [113]. T cells from patients with NASH-
related HCC had higher levels of CTLA-4 and OX40,
which was also associated with certain serum fatty acid
levels; whereas patients with HCV-related HCC had
higher numbers of circulating CD45RA− Tregs [114]. A
recently published analysis of hepatitis B (HBV)-positive
HCC versus non-virally related HCC using mass cytom-
etry and RNA sequencing found several distinguishing
characteristics based on etiology. In non-viral HCC,
there is generally more IFNγ, IL-17, Granzyme B, and
TNFα whereas virally-associated tumors have increased
PD-1 expression on T cells, supporting a generally sup-
pressive environment created by HBV [115]. Tregs and
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CD8+ resident memory T cells (TRM) were more abun-
dant in tumors in HBV+ patients than HBV− patients
and had different transcriptome signatures, such as in-
creased IL-10 signaling pathway in Tregs and more
exhaustion-related genes in TRM in HBV+ patients
[115]. In contrast, TIM-3+CD8+ T cells and CD244+ NK
cells were more abundant in the tumors of non-viral
HCC [115].
Regardless of initiating injury, impaired liver function
leads to alteration of the microbiome and resulting host:
microbial interactions and downstream metabolic path-
ways [56]. Mice treated with antibiotics to deplete gut
microbes had less microbial-driven conversion of pri-
mary to secondary bile acids which resulted in enhanced
CXCL16 expression and recruitment of activated type I
CXCR6+ NK T cells, protecting against liver tumor
growth [71]. Given the effect of liver dysfunction on bac-
terial translocation and recent studies illuminating the
role of the microbiome in response to checkpoint inhib-
ition, there is likely many mechanisms by which the al-
tered gut flora of patients with HCC shapes the immune
response within the liver.
Protective and tumor-antigen-specific immune responses
in HCC
Effector cells that are found within tumors and peripheral
blood of HCC patients are generally dysfunctional, although
existence of certain effector cells and other immune media-
tors are shown to be associated with improved prognosis,
such T and NK cells, suggesting a productive immune re-
sponse to HCC is possible [116, 117]. TCRγδ T cells are ex-
panded in the blood of liver cancer patients and show
capability to kill tumor cells ex vivo [118]. A 14-gene panel
of immune-related genes (including TNF, CD8A, IFNG, and
various chemokines and TLRs) predicted prognosis in early
stage but not late stage HCC, suggesting that a protective im-
mune microenvironment can exist in early but not late stage
HCC [119]. CXCL10, CCL5 and CCL2 correlated with infil-
tration of CD8+ T cells, Th1 CD4+ T cells, and NK cells
[119]. Cytokines such as IFNγ, TNFα, and TLR3 ligands
could induce production of these chemokines by cancer cells
which then serve to recruit T and NK cells [119]. Myeloid
cells can be induced via CpG oligonucleotides to stimulate
CD8+ T cells, demonstrating the dichotomous nature of
myeloid compartment under different conditions [120]. V-
domain Ig suppressor of T cell activation (VISTA), while
thought to be a negative regulator of T cells, is associated
with better prognosis in HCC, in contrast to its association
with worse outcomes in other tumor types [121–123]. The
association of VISTA with tumor-infiltrating CD8+ T cells in
HCC may be a signal of activated, albeit exhausted, effector
cells that are protective against tumor progression whereas
in melanoma and pancreatic cancer, VISTA was mainly
expressed by myeloid subsets.
Tumor antigen-specific responses can occur in HCC,
and the association of HCC with pathogens such as the
hepatitis viruses may be an opportunity for targeting
non-host antigens that will be recognized as foreign to
the immune system. Spontaneous tumor antigen-specific
T cell responses have been detected in HCC, including
in a patient that had a complete response following
treatment with sorafenib and in another patient cohort
following local or systemic chemotherapy [124, 125].
TCR sequencing identified a concentration of shared
TCR α and β chains in liver tumors compared to T cells
in blood or adjacent non-tumor liver, implying clonal T
cells within tumors [96]. Another group found that while
there were detectable T cell responses to tumor-
associated antigens, responses declined with advancing
disease and tumor antigen-specific CD8+ T cells were
dysfunctional with low production of IFNγ, Granzyme B,
and perforin [126]. In a mouse model of HCC driven by
virally-induced SV40 large T antigen, there is clearance
of most virally-infected cells and in cells that persist,
they retain expression of viral products [127]. However,
despite the frequency of virally-associated HCC, the
response to CPI does not occur in the same high pro-
portion of patients as in other virally-associated cancers
such as Merkel cell carcinoma, suggesting that anti-viral
immune responses are not sufficient for a successful re-
sponse to immunotherapy [128].
Changes in the HCC tumor microenvironment with the
use of CPI
Due to limited clinical data overall thus far for the use
of CPI in HCC, correlative studies using samples from
CPI-treated liver cancer patients has lagged behind that
in other cancer types. Therefore, most data we have re-
garding the changes in the liver post-CPI are derived
from mouse models of HCC in which various check-
point inhibitors have been used. In mouse models of
HCC, anti-PD-1 has been shown to have activity both as
monotherapy and in combination with other anti-cancer
therapies. Due to the heterogeneity of models available,
of which none wholly replicates the process of HCC ini-
tiation and progression in humans, the results are vari-
able and based on the model used [129]. Importantly,
anti-PD-1 has been shown to have activity in mouse
models of HCC that incorporate a fibrotic liver micro-
environment and that replicate findings seen in human
tumors such as progressively exhausted PD-1+ CD8+ T
cells and accumulation of Tregs, as well as in patients
with Child Pugh B liver dysfunction [22, 130]. Sorafenib
therapy upregulated PD-L1 in orthotopic liver tumors
and caused the accumulation of suppressive macro-
phages and Tregs which could be mitigated with a
CXCR4-antagonist [131]. Anti-PD-1 showed synergy
with the combination of the CXCR4 antagonist and
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sorafenib although not with sorafenib alone, demonstrat-
ing that a multi-targeted approach may be needed to
overcome a suppressive microenvironment [131]. This
model is particularly clinically relevant as many HCC pa-
tients will have been treated with tyrosine kinase inhibi-
tors prior to CPI which may alter the tumor
microenvironment.
To date, the published clinical trials of CPI in HCC have
reported relatively limited immune profiling analyses on
blood and archival tumor samples in subsets of patients. In
the CheckMate040 and KEYNOTE-224 clinical trials of anti-
PD-1 therapy, there were no cases of HCV or HBV viral re-
activation. In CheckMate040, there were transient decreases
in HCV viral load in HCV-infected patients [15, 16]. In pa-
tients with HCV and HCC treated with anti-CTLA-4, the
majority had a decrease in viral load, including three patients
with a transient complete viral response; however, anti-viral
T cell responses did not correlate with tumor response [18].
In another study combining anti-CTLA-4 therapy with abla-
tion, anti-viral responses were again seen in HCV+ patients
and those patients who did not have an anti-viral response
also did not benefit in terms of tumor control [17]. This clin-
ical trial included on-treatment biopsies at the time of abla-
tion, which revealed that CD8+ T cell infiltration at six weeks
after initiation of anti-CTLA-4 correlated with tumor re-
sponse [17]. In other tumor types, PD-L1 has been used as a
predictor of response to anti-PD-1 CPI. In CheckMate040,
no association was found between radiographic response and
tumor cell expression of PD-L1, whereas the KEYNOTE-224
trial of pembrolizumab, which used a combined score of the
tumor and microenvironment immune cell PD-L1 expres-
sion, found a correlation between PD-L1-expression and re-
sponse [15, 16].
Conclusion
The unique immunobiology of the liver promotes onco-
genesis and tumor tolerance under conditions of fibrosis
and chronic inflammation, while also presenting an op-
portunity for therapeutic targeting with immune check-
point inhibitors. While toxic and pathogenic insults may
provide neo-epitopes and pathways to target with anti-
cancer agents, the background of chronic inflammation
promotes immune suppression in an immune organ
already predisposed towards tolerance. Beyond immune
cell populations unique to the liver, other factors associ-
ated with chronic liver disease may also shape the re-
sponse to immunotherapy. The microbiome has been
demonstrated to predict response to CPI in other malig-
nancies and is particularly relevant to HCC, due to the
altered microbiome in the setting of gut translocation in
chronic liver disease patients [56, 132]. The microbial
contribution, including both gut commensals and patho-
genic hepatitis viruses, to oncogenesis and response to
CPI should be two key focus areas of future
investigation. While mouse models cannot fully recap-
itulate the complex interaction of fibrosis caused by vari-
ous toxic and pathogenic insults, the altered liver
architecture seen in cirrhosis, and human immune cell
populations unique to the liver, several relevant models
have thus far demonstrated the benefits to using com-
bination therapies to simultaneously stimulate effector T
cells and inhibit suppressive immune populations [130,
131]. Compared to tumor types which are considered
immunologically “cold” (having very little immune cell
infiltration), the rich infiltrates of leukocytes within the
liver present an opportunity to use novel immunother-
apy combinatorial strategies to re-polarize immune cells
to a productive anti-cancer response. Furthermore, strat-
egies targeting suppressive populations such as HSCs
and MDSC that worsen fibrosis and impair protective T
cell function are a potential path forward to enhancing
the efficacy of CPI. Additionally, tumor cell intrinsic
mechanisms of resistance to CPI should be explored.
Given that the majority of HCC patients have developed
cancer in a background of impaired liver function and
liver inflammation, the clinical need for strategies that
are both effective and safe in this population is of great
importance, as well as determining how best to sequence
or combine available agents for HCC. Identification of
biomarkers of immune response is also paramount in
guiding choice of individual treatments and sequencing
therapy. Further correlative and basic science studies
should reveal the full potential of the immune system to
re-shape the dysfunctional liver tumor microenviron-
ment and overcome the barriers to successful anti-
cancer immunotherapy.
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